StocktoriaDecoy Therapeutics Inc. DCOY
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
4/9
Piotroski F — financial health
—
Altman Z″ — distress risk
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | — | — | — | $0 | $1.8M |
| Operating income | -$12.6M | -$5.7M | -$12.9M | -$31.8M | -$12.8M |
| Net income | -$12.5M | -$5.6M | -$12.5M | -$31.6M | -$12.8M |
| Operating cash flow | -$4.8M | -$4.5M | -$12.8M | -$17.6M | -$10.2M |
| Free cash flow | — | — | — | — | -$10.2M |
| Total assets | $11.1M | $3.0M | $6.6M | $14.7M | $40.8M |
| Total liabilities | $5.2M | $1.5M | $1.3M | $4.3M | $2.1M |
| Shareholders' equity | $5.9M | $1.5M | $5.3M | $10.4M | $38.7M |
| Ratios | |||||
| Operating margin | — | — | — | — | -696.3% |
| Net margin | — | — | — | — | -693.8% |
| FCF margin | — | — | — | — | -554.3% |
| Return on assets | -113.2% | -184.4% | -190.4% | -215.7% | -31.3% |
| Return on equity | -212.6% | -368.8% | -237.2% | -304.4% | -33.0% |
| Current ratio | 2.13 | 1.98 | — | — | — |
| Revenue growth | — | — | — | -100.0% | -64.8% |
Why these scores methodology →
Piotroski F-score: 4/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: n/a
Not applicable (financials/insurer or missing inputs).
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001615219 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.